Clinical Trial Update: Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years) [Phase 3]

View source ↗

Summary

Phase 3 trial update for the GSK-580299 vaccine in healthy women; study completed with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Papillomavirus Infections

Drugs mentioned

• GSK 580299 vaccine (human papillomavirus vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 3 | Status: COMPLETED | Results posted: 2013-12-03